Download interactions: TXT MITAB-2.5
Interaction | Interactor | Experiments | Homologs | Category | Interaction Score |
Confidence |
---|---|---|---|---|---|---|
A1Z6Z9
Dilute class unconventional myosin, isoform A |
1 |
17 |
High-throughput |
0.575 | High |
|
TPM1
Tropomyosin-1, isoforms 9A/A/B |
1 |
7 |
High-throughput |
0.575 | High |
|
Q8IN65
Mitochondrial calcium uptake 3, isoform B |
1 |
3 |
High-throughput |
0.553 | High |
|
MLC2
Myosin-2 essential light chain |
1 |
19 |
High-throughput |
0.514 | High |
|
DNAT
Arylalkylamine N-acetyltransferase 1 |
1 |
1 |
High-throughput |
0.457 | High |
|
Q9VCY2
GH01248p |
1 |
1 |
High-throughput |
0.457 | High |
|
Q9VNK6
cathepsin L |
1 |
2 |
High-throughput |
0.457 | High |
|
CAPZB
F-actin-capping protein subunit beta |
1 |
3 |
High-throughput |
0.445 | High |
|
Q7K3X8
Alkaline phosphatase |
1 |
1 |
High-throughput |
0.437 | High |
|
Q8MR63
Aldose 1-epimerase |
1 |
1 |
High-throughput |
0.437 | High |
|
Q8SXB3
L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase |
1 |
1 |
High-throughput |
0.437 | High |
|
Q9W3B3
Uroporphyrinogen-III synthase |
1 |
1 |
High-throughput |
0.437 | High |
|
EFHD2
EF-hand domain-containing protein D2 homolog |
1 |
5 |
High-throughput |
0.407 | High |
|
CAPZA
F-actin-capping protein subunit alpha |
1 |
4 |
High-throughput |
0.407 | High |
|
Q9W478
RE43153p |
1 |
1 |
High-throughput |
0.407 | High |
|
Q9I7S2
RH22417p |
1 |
0 |
High-throughput |
0.249 | Low |
|
MINY3
Ubiquitin carboxyl-terminal hydrolase MINDY-3 homolog |
1 |
0 |
High-throughput |
0.249 | Low |
|
Q7JZC9
Nnf1a |
1 |
0 |
High-throughput |
0.232 | Low |
|
Q9I7N2
Nucleoporin NUP42 |
1 |
0 |
High-throughput |
0.232 | Low |
|
Q9VB93
RE23868p |
1 |
0 |
High-throughput |
0.232 | Low |
|
Q9VQJ8
Protein-lysine N-methyltransferase CG9643 |
1 |
0 |
High-throughput |
0.232 | Low |
|
Q9VXV4
RH04535p |
1 |
0 |
High-throughput |
0.232 | Low |
|
Q9W3B2
Protein MAK16 homolog |
1 |
0 |
High-throughput |
0.232 | Low |
Service provided by Combinatics, Japan
Last updated: 11Aug2025